ArticleNeurology(R) neuroimmunology & neuroinflammation2022
Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- Intranodal expansion of follicular T helper cells in patients with multiple sclerosis.JCI insight · 2025Article
- New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.Annals of neurology · 2025Review
- Aging-dependent change in Th17 and cytokine response in multiple sclerosis.Journal of neuroinflammation · 2025Article
- Subcortical plaques and inflammation reflect cortical and meningeal pathologies in progressive multiple sclerosis.Brain pathology (Zurich, Switzerland) · 2025Article
- Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS.Frontiers in immunology · 2025Review
- CXCL13 as a Biomarker: Background and Utility in Multiple Sclerosis.Biomolecules · 2024Review
- CXCL13: a common target for immune-mediated inflammatory diseases.Clinical and experimental medicine · 2024Review
- Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine.Frontiers in immunology · 2024Article
- The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome.International journal of molecular sciences · 2023Article
- Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.Frontiers in immunology · 2023Article
- T follicular helper cells and T follicular regulatory cells in autoimmune diseases.Frontiers in immunology · 2023Review
- The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.Biomedicines · 2022Review
- Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesFollicular helper T (Tfh) cells play a critical role in protective immunity helping B cells produce antibodies against foreign pathogens and are likely implicated in the pathogenesis of various autoimmune diseases. The purpose of this study was to investigate the role of Tfh cells in the pathogenesis of multiple sclerosis (MS).
methodsUsing flow cytometry, we investigated phenotype, prevalence, and function of Tfh cells in blood and CSF from controls and patients with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). In addition, an in vitro blood-brain barrier coculture assay of primary human astrocytes and brain microvascular endothelial cells grown in a Boyden chamber was used to assess the migratory capacity of peripheral Tfh cells.
resultsThis study identified 2 phenotypically and functionally distinct Tfh cell populations: CD25 DISCUSSION: Our study indicates substantial changes in intrathecal Tfh dynamics, particularly in patients with RRMS, and suggests that the intrathecal inflammatory environment in patients with RRMS promotes recruitment of peripheral Tfh cells rather than the Tfh cells having an increased capacity to migrate to CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.